DDrare: Database of Drug Development for Rare Diseases

Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis", "TEN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Clobetasol; Clobetasol 0.05% ointment; Cyclosporine; Cyclosporine 5 mg/kg bid days 0-14; Etanercept; Etanercept 50 mg sc day 0 and day 3; Harmonized supportive care; Infliximab; Intravenous immunoglobulin; Isotretinoin; Methylprednisolone; NaCl 0.9%; Palifermin; Prednisolone; Recombinant granulocyte - colony stimulating factor; Remicaide (infliximab); Site specific standard of care comparison; Topical infliximab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02739295 (ClinicalTrials.gov)	July 2016	4/4/2016	G-CSF in the Treatment of Toxic Epidermal Necrolysis	Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis	Stevens - Johnson Syndrome	Drug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9%	University of Liege	NULL	Recruiting	18 Years	N/A	All	10	Phase 4	Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02739295
(ClinicalTrials.gov)

July 2016

4/4/2016

G-CSF in the Treatment of Toxic Epidermal Necrolysis

Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis

Stevens - Johnson Syndrome

Drug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9%

University of Liege

NULL

Recruiting

18 Years

N/A

All

Phase 4

Belgium